FDAsafety guidance66% confidence
FDA AP — DOXYCYCLINE HYCLATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA090505. Sponsor: IMPAX LABS INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: DOXYCYCLINE HYCLATE.
Supporting Context
- Therapeutic area
- Infectious Disease · Antibiotic
- Sub-indication
- General
Related signal: Lupin's Doxycycline ANDA204234 Receives AP Status from FDA